🔎 Trials Near Me

Akèy › Kansè lestomak › Virginia › Arlington

Etid klinik pou Kansè lestomak nan Arlington, VA

20 etid pou Kansè lestomak ap chèche patisipan nan sit nan ak bò kote Arlington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

The Vanguard Study: Testing a New Way to Screen for Cancer

Ap rekriteVolontè an sante akeyi
  • Inova Schar Cancer Institute, Fairfax · 11 mi lwen
  • Inova Fair Oaks Hospital, Fairfax · 11 mi lwen
Laj 45 a 75 · Tout sèks · Mizajou Oct 5, 2026 · NCT06995898

Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

Ap rekriteFaz 1/2
  • NEXT Virginia, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07529808

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Ap rekriteFaz 1
  • NEXT Virginia, Fairfax · 11 mi lwen
Laj 19 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06586957

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Ap rekriteFaz 2/3
  • Virginia Cancer Specialists, PC, Arlington
  • Virginia Cancer Specialists, PC, Fairfax · 11 mi lwen
  • Virginia Cancer Specialists, PC, Reston · 14 mi lwen
  • ak 1 plis
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07392892

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Ap rekriteFaz 1/2
  • NEXT Oncology Virginia, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Ap rekriteFaz 1
  • Virginia Cancer Specialists, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Ap rekriteFaz 1
  • NEXT Oncology - Virginia Cancer Specialists, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Ap rekriteFaz 1
  • NEXT Virginia, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT07227168

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Ap rekriteFaz 1/2
  • Research Site, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT07115043

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Ap rekriteFaz 1
  • NEXT Virginia, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Aug 13, 2026 · NCT07066657

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

Ap rekriteFaz 1/2
  • Clinical Trial Site, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07749586

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Ap rekriteFaz 1
  • NEXT Virginia, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT05208762

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Ap rekriteFaz 1
  • Virginia Cancer Specialists, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT06657144

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Ap rekriteFaz 1
  • Virginia Cancer Specialists, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Ap rekriteFaz 1/2
  • Virginia Cancer Specialists, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Mar 27, 2026 · NCT06395519

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

Ap rekriteFaz 1
  • NEXT Virginia, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Jan 21, 2026 · NCT07317505

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Ap rekriteFaz 1
  • Dren Investigational Site, Fairfax · 11 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Jan 7, 2026 · NCT06999187

Etid Kansè lestomak nan lòt vil

Lòt etid nan Arlington

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.